SCHEMBL21069308

SCHEMBL21069308

NCCCCCOCCOCCOCCCCCNC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 2/20 0.50
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
TPSAB1 Q15661 2/20 0.38
TPSD1 Q9BZJ3 2/20 0.38
TPSG1 Q9NRR2 2/20 0.38
TLR2 O60603 1/20 0.38
GNAI3 P08754 1/20 0.38
GNAO1 P09471 1/20 0.38
GNAI1 P63096 1/20 0.38
EPHX2 P34913 5/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
PLG P00747 1/20 0.38
LMNA P02545 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
SLC6A2 P23975 1/20 0.38
RECQL P46063 1/20 0.38
SLC6A3 Q01959 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069585 1.00 PAOX (0.50) PAOXMAOAMAOBTPSAB1TPSD1
SCHEMBL21071023 0.98 PAOX (0.52) PAOXMAOAMAOBTPSAB1TPSD1
SCHEMBL22326140 0.98 PAOX (0.52) PAOXMAOAMAOBTPSAB1TPSD1
SCHEMBL22326266 0.93 PAOX (0.41) PAOXEPHX2CYP2C19
SCHEMBL22326246 0.93 TLR2 (0.43) PAOXMAOAMAOBTLR2EPHX2
SCHEMBL27160303 0.91 TLR2 (0.41) PAOXTLR2EPHX2MEN1ALDH1A1
SCHEMBL22326245 0.91 PAOX (0.38) PAOXEPHX2ALDH1A1CYP2C19
SCHEMBL25369676 0.89 PAOX (0.39) PAOXEPHX2ALDH1A1CYP2C19
SCHEMBL21806080 0.89 PAOX (0.39) PAOXTLR2ALDH1A1RECQL
SCHEMBL2330619 0.89 PAOX (0.39) PAOXTLR2ALDH1A1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 EP disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PAOX 1862/4885MAOA 2771/4885MAOB 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.